An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

XIIDRA®

Drug Information Related Patent
Hold Company
NOVARTIS
Learn More
Dosage and Administration
SOLUTION/DROPS;OPHTHALMIC
Specification
5%
Indication
XIIDRA® is used to treat the signs and symptoms of dry eye disease (DED).
Use
Instructions for Use
API
LIFITEGRAST
API Structure
We Supply
LIFITEGRAST
Note:

Facility GMP
DMF

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
101240002024/11/5
110586772033/12/18
73149382025/3/10
77454602024/11/5
77907432024/11/5
79281222024/11/5
80840472026/5/17
81686552029/5/9
83677012029/4/15
85924502026/5/17
89275742030/11/12
90855532033/7/25
92161742024/11/5
93530882030/10/21
94470772029/4/15
98901412030/10/21
API Patent
Patent NoExpiration Date
101240002024/11/5
73149382025/3/10
77454602024/11/5
77907432024/11/5
79281222024/11/5
80840472026/5/17
81686552029/5/9
85924502026/5/17
92161742024/11/5

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top